[1] |
Chen J, Xia C, Duan T, et al. Macrotrabecular-massive hepatocellular carcinoma: imaging identification and prediction based on gadoxetic acid-enhanced magnetic resonance imaging[J]. Eur Radiol, 2021, 31(10): 7696-7704. DOI: 10.1007/s00330-021-07898-7.
pmid: 33856520
|
[2] |
张玉敏, 赵现伟, 何前进, 等. 超声造影联合血清CXCL8、CXCR2在原发性肝癌经导管动脉化疗栓塞术后疗效评估中的价值分析[J]. 国际肿瘤学杂志, 2022, 49(10): 592-596. DOI: 10.3760/cma.j.cn371439-20220429-00117.
|
[3] |
Liu F, Hou B, Li Z, et al. Microwave ablation of multifocal primary liver cancer guided by real-time 3.0T MRI[J]. Int J Hyperthermia, 2023, 40(1): 2228519. DOI: 10.1080/02656736.2023.2228519.
|
[4] |
Asano K, Kageyama K, Yamamoto A, et al. Transcatheter arterial chemoembolization for treatment-naive hepatocellular carcinoma has different treatment effects depending on central or peripheral tumor location[J]. Liver Cancer, 2023, 12(6): 576-589. DOI: 10.1159/000530441.
pmid: 38058422
|
[5] |
Herkel J, Schmidt-Arras D. Mediators of liver inflammation and carcinogenesis[J]. Semin Immunopathol, 2021, 43(4): 477-479. DOI: 10.1007/s00281-021-00880-x.
pmid: 34528106
|
[6] |
Wu YL, Fulgenzi CAM, D'Alessio A, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as prognostic biomarkers in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab[J]. Cancers (Basel), 2022, 14(23): 5834. DOI: 10.3390/cancers14235834.
|
[7] |
Tiegs G, Horst AK. TNF in the liver: targeting a central player in inflammation[J]. Semin Immunopathol, 2022, 44(4): 445-459. DOI: 10.1007/s00281-022-00910-2.
pmid: 35122118
|
[8] |
中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017年版)[J]. 中华肝脏病杂志, 2017, 25(12): 886-895. DOI: 10.3760/cma.j.issn.1007-3418.2017.12.002.
|
[9] |
Naghashzadeh F, Noorali S, Hosseini-Baharanchi FS, et al. Comparison of scores for child-pugh criteria and standard and modified models for end-stage liver disease to assess cardiac hepatopathy in heart transplant recipients[J]. Exp Clin Transplant, 2021, 19(9): 963-969. DOI: 10.6002/ect.2020.0559.
pmid: 34545779
|
[10] |
Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602[J]. Ups J Med Sci, 2013, 118(1): 16-22. DOI: 10.3109/03009734.2012.729104.
|
[11] |
中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版)[J]. 肿瘤防治研究, 2022, 49(3): 251-276. DOI: 10.3971/j.issn.1000-8578.2022.03.0001.
|
[12] |
Xie DY, Zhu K, Ren ZG, et al. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights[J]. Hepatobiliary Surg Nutr, 2023, 12(2): 216-228. DOI: 10.21037/hbsn-22-469.
|
[13] |
赵剑强, 朱青峰, 刘晓, 等. 基于三维可视化技术对巨块型肝癌肝动脉血管分布规律的分析与研究[J]. 中国医学物理学杂志, 2021, 38(1): 40-46. DOI: 10.3969/j.issn.1005-202X.2021.01.007.
|
[14] |
Spiliotis AE, Gäbelein G, Holländer S, et al. Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis[J]. Radiol Oncol, 2021, 55(3): 247-258. DOI: 10.2478/raon-2021-0030.
pmid: 34167181
|
[15] |
Wang X, Li M, Wang J, et al. The effect of nano-albumin paclitaxel on the early postoperative recurrence of primary liver cancer[J]. J Nanosci Nanotechnol, 2020, 20(12): 7283-7288. DOI: 10.1166/jnn.2020.18710.
pmid: 32711592
|
[16] |
宋佳, 胡钦勇. TACE联合靶向、免疫治疗在BCLC B/C期肝细胞癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 550-554. DOI: 10.3760/cma.j.cn371439-20220520-00107.
|
[17] |
Yang YM, Kim SY, Seki E. Inflammation and liver cancer: molecular mechanisms and therapeutic targets[J]. Semin Liver Dis, 2019, 39(1): 26-42. DOI: 10.1055/s-0038-1676806.
pmid: 30809789
|
[18] |
Cupp MA, Cariolou M, Tzoulaki I, et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies[J]. BMC Med, 2020, 18(1): 360. DOI: 10.1186/s12916-020-01817-1.
pmid: 33213430
|
[19] |
Li CH, Palanisamy K, Li X, et al. Exosomal tumor necrosis factor-α from hepatocellular cancer cells (Huh-7) promote osteoclast differentiation[J]. J Cell Biochem, 2021, 122(11): 1749-1760. DOI: 10.1002/jcb.30127.
|
[20] |
Geh D, Leslie J, Rumney R, et al. Neutrophils as potential therapeutic targets in hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(4): 257-273. DOI: 10.1038/s41575-021-00568-5.
pmid: 35022608
|
[21] |
Minici R, Siciliano MA, Ammendola M, et al. Prognostic role of neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-C reactive protein ratio (LCR) in patients with hepatocellular carcinoma (HCC) undergoing chemoembolizations (TACE) of the liver: the unexplored corner linking tumor microenvironment, biomarkers and interventional radiology[J]. Cancers (Basel), 2022, 15(1): 257. DOI: 10.3390/cancers15010257.
|
[22] |
Heinrich B, Gertz EM, Schäffer AA, et al. The tumour micro-environment shapes innate lymphoid cells in patients with hepatocellular carcinoma[J]. Gut, 2022, 71(6): 1161-1175. DOI: 10.1136/gutjnl-2021-325288.
|
[23] |
Zong C, Meng Y, Ye F, et al. AIF1+ CSF1R+ MSCs, induced by TNF-α, act to generate an inflammatory microenvironment and promote hepatocarcinogenesis[J]. Hepatology, 2023, 78(2): 434-451. DOI: 10.1002/hep.32738.
|
[24] |
Wungu CDK, Riyanto FC, Prabowo GI, et al. Association between five types of tumor necrosis factor-α gene polymorphism and hepatocellular carcinoma risk: a meta-analysis[J]. BMC Cancer, 2020, 20(1): 1134. DOI: 10.1186/s12885-020-07606-6.
pmid: 33228594
|
[25] |
朱倩, 卢贵余, 桂芬芳, 等. TNF-α对肝癌细胞NF-κB信号通路活化的影响及临床意义[J]. 河北医药, 2018, 40(24): 3700-3703. DOI: 10.3969/j.issn.1002-7386.2018.24.004.
|